Patient-reported outcomes in moderate-to-severe allergic asthmatics treated with omalizumab: a systematic literature review of randomized controlled trials

Abstract

Objective: Randomized controlled trials (RCTs) have established the safety and efficacy of omalizumab on clinical parameters, and have also evaluated its impact on patient-reported outcomes (PROs). The purpose of this systematic literature review was to review published data based on PRO endpoints in order to determine the benefit of omalizumab as add-on therapy to inhaled corticosteroids in patients with moderate-to-severe persistent allergic asthma. Methods: A systematic literature review was conducted of reference databases and recent conferences. RCTs of add-on omalizumab therapy in adults, adolescents, and children with moderate-to-severe persistent asthma were included. Two researchers independently screened and reviewed articles with regards to inclusion and exclusion criteria for relevant studies. Results: Twenty-six trials met the criteria for inclusion. Of these, PRO measures were included in 19 trials to capture the impact of omalizumab on symptoms, 11 assessed patients for health-related quality-of-life (HRQoL), and four evaluated asthma control. Other PROs related to global evaluation of treatment effectiveness and work productivity. Overall, results demonstrated a significant difference across most PROs in favor of omalizumab add-on therapy vs placebo or comparators. Conclusions: PROs are an integral part of outcome assessment in clinical trials related to asthma. The RCTs reviewed demonstrate that omalizumab treatment improves PROs in patients with moderate-tosevere persistent allergic asthma, particularly symptom control and HRQoL.ARTICLE HISTORY

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma

“…Aligned with our results, previous SR of benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab in severe asthma reported a reduction to approximately half of exacerbations, and an improvement in health‐related QoL scores, asthma control and FEV 1 . However, there are some important differences that need to be mentioned.…”

Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study

“…While PROs can provide important insights about the burden of the disease and the efficacy of the treatment, sometimes, especially in asthma, improvement of clinical parameters may not correlate well with the patient experience [ 37 ]. But, here we have shown that the treatment of SAA with omalizumab is able to improve not only the clinical parameters including ACQ, exacerbation rate and FEV 1 but also the PROs.…”

Impact of reslizumab on outcomes of severe asthmatic patients: current perspectives

“… 30 All the registered studies evaluating the efficacy and safety of reslizumab in asthma patients include the assessment of PROs as primary 22 or secondary outcomes. 29 – 31 In the study by Castro et al, 22 the primary end point was the change of asthma control (assessed by ACQ-7) 32 in patients who were treated with reslizumab or placebo for 15 weeks. The mean change in ACQ-7 score from baseline to the study end was modest and did not achieve statistical significance (−0.7 in the reslizumab group and −0.3 in the placebo group, p = 0.0541).…”